BioSenic Past Earnings Performance
Past criteria checks 0/6
BioSenic's earnings have been declining at an average annual rate of -843.9%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 104.1% per year.
Key information
-843.9%
Earnings growth rate
-950.0%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 104.1% |
Return on equity | n/a |
Net Margin | -5,299.8% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BioSenic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1 | -29 | 4 | 4 |
30 Jun 23 | 1 | -23 | 3 | 3 |
31 Mar 23 | 0 | -13 | 2 | 2 |
31 Dec 22 | 0 | -3 | 2 | 1 |
31 Dec 21 | 0 | -1 | 1 | 1 |
Quality Earnings: BT1 is currently unprofitable.
Growing Profit Margin: BT1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BT1's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare BT1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BT1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: BT1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.